Prafulla M. Sabale. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 7(2), 2019, 640-645.

**Research Article** 



# Asian Journal of Research in Chemistry and Pharmaceutical Sciences

Journal home page: www.ajrcps.com



## MOLECULAR DOCKING STUDIES ON CARBAZOLE DERIVATIVES

Prafulla M. Sabale\*<sup>1</sup>, Potey Lata<sup>1</sup>, Kadkanje Sandip<sup>1</sup>

<sup>1\*</sup>Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur-440033, Maharashtra, India.

## ABSTRACT

Carbazole is one of the most important nitrogen containing fused heterocyclic moiety in various chronic as well as other diseases. The main objective of molecular docking is to predict the biological activity of given ligand. This work has been focus on the carbazole moiety as anti-microbial agents, present work emphasize the flexible and extra precision docking simulation on eighteen different Carbazole substituted derivatives in order to evaluate their affinity to bacterial proteins for antibacterial and antifungal activity against *DNA gyrase* (PDB:1KZN) and *Lanosterol 14-a-Demethylase* (PDB:1EA1) enzymes respectively by Maestro 11.5 Schrodinger software in order to choose the derivatives which shows good interactions with target protein. All the compound shows best docking results compared to Chloramphenicol and Fluconazole as standard drugs. Compound C<sub>16</sub> shows -5.373 docking score as standard Chloramphenicol itself shows -5.110 docking score against *DNA Gyrase* enzyme for anti-bacterial agents. Whereas in anti-fungal study, the compound Ca<sub>1</sub> gives - 9.869 docking score as standard Fluconazole gives -7.789 docking score against *Lanosterol 14-a-Demethylase* enzyme. The results may conclude that Carbazole may serve as useful hits in the development of clinically useful anti-microbial agents.

## **KEYWORDS**

Carbazole, DNA gyrase enzyme, Lanosterol 14-a-Demethylase enzyme, Molecular docking studies and Antimicrobial activity.

## Author for Correspondence:

Prafulla M. Sabale, Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, India.

Email: prafullasable@yahoo.com

Available online: www.uptodateresearchpublication.com

## INTRODUCTON

The antimicrobial agents are the substances that kills or inhibits the growth of microbes such as bacteria, fungi, or viruses. Antimicrobial drugs either kill microbes (microbicidal) or prevent the growth of microbes (microbistatic). Antimicrobial drugs have generated a dramatic change not only of the treatment of infectious diseases but of a destiny of humanity<sup>1</sup>. If an inappropriate antimicrobial

April – June

agent happens to be chosen for the treatment of infection with drug-resistant microorganisms, the therapy may not attains an advantageous effect, and furthermore, may shows to a poor prognosis<sup>2</sup>. Special focus on the history of human diseases, infectious diseases have considered for a very large proportion of diseases as a whole<sup>3</sup>. Recent focus in the antimicrobial drug research is on the development of agents inhibiting the enzyme targets involved in potential role in the life cycle of the pathogen<sup>4</sup>. DNA gyrase, the class of topoisomerase and is a subclass of Type II topoisomerases is one of the key enzymes involved in the microbial DNA production cycle and has been considered as a promising target in antibacterial screening<sup>5,6</sup>. Similarly, Lanosterol 14a-demethylase (CYP51A1) is a cytochrome P450 enzyme. The demethylated products of the CYP51 reaction are vital intermediates in pathways leading to the formation of cholesterol in humans, ergosterol in fungi, and other types of sterols in plants, hence it should be the promising target in the antifungal screening<sup>7</sup>. Competitive and non-competitive inhibition of both DNA gyrase and Lanosterol  $14\alpha$ -demethylase are considered as antimicrobial drugs. Docking was performed against DNA gyrase protein enzyme (PDB ID: 1KZN)<sup>8</sup> and Lanosterol 14 $\alpha$ -demethylase protein enzyme (PDB ID: 1EA1)<sup>9</sup> using the GLIDE molecular docking tool implemented in the Schrodinger software.

#### MATERIAL AND METHODS Docking protocol

Molecular docking study on Carbazole derivatives Schrödinger carried out by software was Maestro11.5v in order to develop selective antimicrobial agents. The docking study of eighteen thiazolidine substituted Carbazole compounds was carried out using GLIDE (Grid Based Ligand Docking and Energetics) module of Maestro 11.5 Schrodinger software. The molecule were docked on the DNA gyrase protein enzyme (PDB ID: 1KZN) and Lanosterol  $14\alpha$ -demethylase protein enzyme (PDB ID: 1EA1) imported from the Protein Data Bank (www.rscb.org).

Available online: www.uptodateresearchpublication.com

The steps are involved in molecular docking studies:-

#### **Ligand Preparation**

The 2D Ligand structures of eighteen Thiazolidine substituted Carbazole derivatives were drawn in MAESTRO workspace using build panel. The Schrödinger ligand preparation was done by using LigPrep panel application and optimize the structure to 3D by minimizing its energy through OPLS-3 force field.

#### **Protein Preparation and its Refinement**

Protein for ligand docking was prepared by using protein preparation Wizard which was used to import, refine and minimize the energy of the DNA Gyrase and Lanosterol 14- $\alpha$ -Demethylase. The protein preparation prior to docking is necessary as the protein obtained from the PDB, Vendors, and other sources often have missing hydrogen, partial charges, side chain, and completely loop regions.

#### **Receptor Grid Generation**

Grid generation required to be performing prior to running a virtual screen with glide. The shape and properties of the receptor has represented in a grid by field that provides progressively more accurate scoring of the ligand poses.

#### Validation of Protein

Ramchandran plot is used for the validation DNA *Gyrase* and *Lanosterol* 14- $\alpha$ -Demethylase receptor has performed to test the reliability and reproducibility of the docking protocols for the study.

#### **Protein-Ligand Docking**

The ligand docking was done flexibly using Standard Precision (SP) mode of GLIDE module and further refinement was done by using extra precision (XP) mode. The ligand docking process helps to predict ligand conformation and orientation (posing) within a targeted binding site and thus results in an accurate structural modeling and correct prediction of activity of ligands.

#### **RESULTS AND DISCUSSION**

All the compounds were docked into the binding site of the enzymes (PDB ID- 1KZN and 1EA1), docking result shows that binding of ligand to protein occur as pre applied constrains with April – June 641

interaction in preferred manner as shown in Table No.1. Best biological activity was predicted on the basis of highest docking score and glide docking energy. Compound  $C_{16}$  has shown good antibacterial activity against DNA Gyrase enzyme with highest docking score (-5.373) and Glide docking energy (-51.560) which is comparable with the standard Chloramphenicol with docking score (-5.110) and glide docking energy (-56.205) as shown in Table No.2. Similarly, Compound Ca1 has shown good antifungal activity against Lanosterol 14ademethylase enzyme with highest docking score (-9.869) and Glide docking energy (-40.599) which is comparable with the standard Fluconazole with docking score (-7.789) and glide docking energy (-45.801) as shown in Table No.3. Hydrogen bonding was observed with oxygen of 4-hydroxyl group for compound (Ca<sub>1</sub>) and the hydrogen of amino group for compound  $(C_{16})$ ,

which indicates that both the compounds bind with the active site in a similar way as the natural substrate which is shown in figure 1 and 2. Compound  $(C_{16})$  has shown the non bonding interactions with GLU 50, ARG 76, ASP 49, ASP 101, ILE 90, PRO 79 and ILE 78 active amino acid residues in binding pocket of DNA Gyrase enzyme and the compound (Ca<sub>1</sub>) shown interactions with MET 433, ARG 96, PHE 83, PHE 78, MET 79, TYR 76, MET 99, SER 252 and GLN 72 amino acid residues in binding pockets of Lanosterol 14ademethylase enzyme, shown in Figure No.1 and 2. Compound C12 and Ca<sub>11</sub> have shown less binding affinity with DNA Gyrase and Lanosterol 14ademethylase enzyme respectively with least docking and glide energy scores it could be because of its inauspicious positioning in contrast to the other active compounds and natural substrate androstenedione in the active site.

## Table No.1: Thiazolidine substituted Carbazole derivatives



Thiazolidine Substituted Carbazole Derivatives

S.No	For Antibacterial		For Antifungal		
1	Code	Ar	Code	Ar	
2	C1	Benzaldehyde	Ca <sub>1</sub>	4-Hydroxybenzaldehyde	
3	$C_2$	3-methoxybenzaldehyde	Ca <sub>2</sub>	4-Methylbenzaldehyde	
4	C <sub>3</sub>	3-Methylbenzaldehyde	Ca <sub>3</sub>	3-Bromobenzaldehyde	
5	$C_4$	Salicylaldehyde	Ca <sub>4</sub>	Benzaldehyde	
6	C <sub>5</sub>	4-Dimethylaminobenzaldehyde	Ca <sub>5</sub>	3-Methylbenzaldehyde	
7	C6	2,4-Dimethoxybenzaldehyde	Ca <sub>6</sub>	4-Chlorobenzaldehyde	
8	C <sub>7</sub>	4-Trifluoromethylbenzaldehyde	Ca <sub>7</sub>	3-methoxybenzaldehyde	
9	$C_8$	4-Chlorobenzaldehyde	Ca <sub>8</sub>	2,3-Dimethoxybenzaldehyde	
10	C <sub>9</sub>	2,4-Dichlorobenzaldehyde	Ca <sub>9</sub>	4-Dimethylaminobenzaldehyde	
11	C <sub>10</sub>	2-Methoxybenzaldehyde	Ca <sub>10</sub>	3-Chlorobenzaldehyde	
12	C <sub>11</sub>	3-Bromobenzaldehyde	Ca <sub>11</sub>	2,4-Dimethoxybenzaldehyde	
13	C <sub>12</sub>	2-Nitrobenzaldehyde	-	-	
14	C <sub>13</sub>	3-Chlorobenzaldehyde	-	-	

Available online: www.uptodateresearchpublication.com Ap

Prafulla M. Sabale. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 7(2), 2019, 640-645.

15	C <sub>14</sub>	4-Nitrobenzaldehyde	_	-
16	C <sub>15</sub>	2,3-Dimethoxybenzaldehyde	-	-
17	C <sub>16</sub>	4-Hydroxybenzaldehyde	-	-
18	C <sub>17</sub>	4-Methylbenzaldehyde	-	-
19	C <sub>18</sub>	4-Methoxybenzaldehyde	-	-
20	Standard	Chloramphenicol	Standard	Fluconazole

#### Table No.2: Docking results for Antibacterial study

S.No	<b>Compound Code</b>	<b>Glide Docking Score</b>	<b>Glide Docking Energy</b>	No. of Hydrogen Bonds
1	$C_1$	-4.625	-48.027	1
2	$C_2$	-4.660	-47.940	1
3	$C_3$	-4.446	-43.378	0
4	$C_4$	-4.801	-49.891	0
5	$C_5$	-4.760	-50.472	0
6	$C_6$	-3.467	-51.213	0
7	$C_7$	-4.643	-49.413	1
8	$C_8$	-2.559	-47.067	0
9	<b>C</b> 9	-4.499	-45.885	0
10	$C_{10}$	-4.418	-47.355	1
11	C <sub>11</sub>	-4.552	-47.390	0
12	C <sub>12</sub>	-1.852	-42.773	0
13	C <sub>13</sub>	-2.574	-41.950	1
14	$C_{14}$	-4.028	-45.022	0
15	C <sub>15</sub>	-4.243	-43.538	0
16	C <sub>16</sub>	-5.373	-51.560	2
17	C <sub>17</sub>	-4.720	-49.040	1
18	C <sub>18</sub>	-4.667	-47.650	1
19	Standard	-5.110	-56.205	2

#### Table No.3: Docking results for Antifungal study

S.No	<b>Compound Code</b>	Glide Docking Score	Glide Docking Energy	No. of Hydrogen Bonds
1	Ca <sub>1</sub>	-9.869	-40.599	1
2	Ca <sub>2</sub>	-9.433	-37.761	0
3	Ca <sub>3</sub>	-9.266	-36.155	0
4	Ca <sub>4</sub>	-8.881	-32.077	0
5	Ca <sub>5</sub>	-8.492	-27.933	0
6	Ca <sub>6</sub>	-8.299	-33.802	0
7	Ca <sub>7</sub>	-6.398	-26.407	0
8	Ca <sub>8</sub>	-5.437	-1.000	0
9	Ca <sub>9</sub>	-4.618	-8.512	0
10	Ca <sub>10</sub>	-3.951	-31.949	0
11	Ca <sub>11</sub>	-3.778	-30.039	0
12	Standard	-7.789	-45.801	0

Available online: www.uptodateresearchpublication.com

Prafulla M. Sabale. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 7(2), 2019, 640-645.



Figure No.1: Docked conformations of compound C<sub>16</sub> along with important amino acid residues of *DNA* gyrase (PDB: 1KZN) enzyme as antibacterial



Figure No.2: Docked conformations of compound Ca<sub>1</sub> along with important amino acid residues of Lanosterol 14α-demethylase (PDB: 1EA1) enzyme as antifungal

#### CONCLUSION

Results of docking study clearly demonstrated that the selected thiazolidine substituted Carbazole derivatives have better binding sites and interactions with selected proteins. The highly précised binding protein interactions leads to greater field interaction with crystallized domain. This can be valuable for synthesis and thereafter biological screening of promising hits.

#### ACKNOWLEDGEMENT

Authors gratefully acknowledge to University Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur for providing Maestro 11.5 Schrodinger software.

#### **CONFLICT OF INTEREST**

We declare that we have no conflict of interest.

Available online: www.uptodateresearchpublication.com

#### **COMPETING INTERESTS**

The authors declare that they have no competing interests.

#### BIBLIOGRAPHY

- 1. Mohammad A. Review on Antimicrobial Agents, Organic and Medicinal Chemistry International Journal, 1(5), 2017, 001-007.
- 2. Perwez A A. Molecular docking studies of novel Carbazole tethered pyrrole derivatives as potent inhibitors of Mycobacterium tuberculosis, *The Pharma Innovation Journal*, 6(9), 2017, 187-189.
- 3. Tomoo S, Keizo Y. History of Antimicrobial Agents and Resistant Bacteria, *Japan Medical Association Journal*, 52(2), 2009, 103-108.
- 4. Fouad R S, Mariam K D, Diana N M, Mohamad K R. Nvel Antimicrobial Agents:

```
April – June
```

Prafulla M. Sabale. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 7(2), 2019, 640-645.

A Review, International Journal of Pharmacy and Technology, 5(4), 2014, 2824-2838.

- Juan J P, Cecylia S L and Patricia G G. Designing Type II Topoisomerase Inhibitors: A Molecular Modeling Approach, *Current Topics in Medicinal Chemistry*, 14(1), 2014, 40-50.
- 6. Muthu K K, Madhavi M K, Kiana N, Aparna S C and Kishor S J. Topoisomerase as target for antibacterial and anticancer drug discovery, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 28(3), 2013, 419-435.
- Galina I L and Michael R W. Sterol 14α-Demethylase Cytochrome P450 (CYP51), a P450 in all Biological Kingdoms, *Biochim Biophys Acta*, 1770(3), 2007, 467-477.
- Sri Dharani R, Ranjitha R, Sripathi R, Ali M K, Ravi S. Docking Studies In Target Proteins Involved In Antibacterial Action Mechanisms: Alkaloids Isolated From Scutellaria Genus, *Asian J Pharm Clin Res*, 9(5), 2016, 121-125.
- 9. Mohammad R K, Love K S, Nema R K, Neelam B. Designing of New Benzotriazole Analogs using Molecular Docking Studies against Receptor 1EA1.Pdb and 1IYL.Pdb for Treatment of Fungal Infection, *Journal of Drug Delivery and Therapeutics*, 7(7), 2017, 139-141.
- 10. Głuszynska A. Biological potential of carbazole derivatives, *European Journal of Medicinal Chemistry*, 94, 2015, 405-426.
- Morris G M, Goodsell D S, Halliday R S, Huey R, Hart W, Belew R K, Olson A J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function, *Journal of Computational Chemistry*, 19(14), 1998, 1639-1662.

- 12. Abagyan R, Totrov M and Kuznetsov D. ICM-A New Method for Protein Modeling and Design: Applications to Docking and Structure Prediction from the Distorted Native Conformation, *Journal of Computational Chemistry*, 15(5), 1994, 488-506.
- Jain A N. Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine, *Journal of Medicinal Chemistry*, 46(4), 2003, 499-511.
- 14. Arndt W, Schmidt K, Reddy R and Knolker H J. Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids, *Chem. Rev*, 112(6), 2012, 3193-3328.
- 15. Asche C, Frank W, Albert A and Kucklaender U. Synthesis, antitumour activity and structure-activity relationships of 5H-benzo[b] carbazoles, *Bioorganic and Medicinal Chemistry*, 13(3), 2005, 819-837.
- 16. Indumathi T, Muthusankar A, Shanmughavel P and Rajendra Prasad K J. Synthesis of hetero annulated carbazoles: exploration of in vitro cytotoxicity and molecular docking studiest, *Med. Chem. Commun*, 4(2), 2013, 450-455.
- 17. Jones G, Willett P, Glen R C, Leach A R and Taylor R. Development and Validation of a Genetic Algorithm for Flexible Docking, *Journal of Molecular Biology*, 267(3), 1997, 727-748.

**Please cite this article in press as:** Prafulla M. Sabale *et al.* Molecular docking studies on carbazole derivatives, *Asian Journal of Research in Chemistry and Pharmaceutical Sciences*, 7(2), 2019, 640-645.